Day vs night

Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial

Peter Pang, John R. Teerlink, Leandro Boer-Martins, Claudio Gimpelewicz, Beth A. Davison, Yi Wang, Adriaan A. Voors, Thomas Severin, Piotr Ponikowski, Tsushung A. Hua, Barry H. Greenberg, Gerasimos Filippatos, G. Michael Felker, Gad Cotter, Marco Metra

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Signs and symptoms of heart failure can occur at any time. Differences between acute heart failure (AHF) patients who present at nighttime vs daytime and their outcomes have not been well studied. Our objective was to determine if there are differences in baseline characteristics and clinical outcomes between AHF patients presenting during daytime vs nighttime hours within an international, clinical trial. Methods This is a post hoc analysis of the RELAX AHF trial, which randomized 1,161 AHF patients to serelaxin vs placebo, both in addition to usual AHF therapy. Prespecified end points of the primary trial were used: dyspnea, 60-day heart failure/renal failure rehospitalization or cardiovascular (CV) death, and 180-day CV death. Both unadjusted and adjusted analyses for outcomes stratified by daytime vs nighttime presentation were performed. Results Of the 1,161 RELAX-AHF patients, 775 (66.8%) patients presented during daytime and 386 (33.2%) at nighttime. Baseline characteristics were largely similar, although daytime patients were more likely to be male, have greater baseline body weight, have higher New York Heart Association class, have history of atrial fibrillation, and have more peripheral edema compared with nighttime patients. No differences in dyspnea relief or 60-day outcomes were observed. However, daytime presentation was associated with greater risk for 180-day CV death after adjustment (hazard ratio 2.28, 95% CI 1.34-3.86; c statistic = 0.82, 95% CI 0.78-0.86). Conclusion In this secondary analysis of the RELAX-AHF trial, baseline characteristics suggest that daytime-presenting patients may have more gradual worsening of chronic HF. Patients with AHF who presented at night had less risk for 180-day CV death, but similar risk for 60-day CV death or rehospitalization and symptom improvement for patients who presented during the daytime.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalAmerican Heart Journal
Volume187
DOIs
StatePublished - May 1 2017

Fingerprint

Heart Failure
Dyspnea
Atrial Fibrillation
Signs and Symptoms
Renal Insufficiency
Edema
Placebos
Body Weight
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Day vs night : Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. / Pang, Peter; Teerlink, John R.; Boer-Martins, Leandro; Gimpelewicz, Claudio; Davison, Beth A.; Wang, Yi; Voors, Adriaan A.; Severin, Thomas; Ponikowski, Piotr; Hua, Tsushung A.; Greenberg, Barry H.; Filippatos, Gerasimos; Felker, G. Michael; Cotter, Gad; Metra, Marco.

In: American Heart Journal, Vol. 187, 01.05.2017, p. 62-69.

Research output: Contribution to journalArticle

Pang, P, Teerlink, JR, Boer-Martins, L, Gimpelewicz, C, Davison, BA, Wang, Y, Voors, AA, Severin, T, Ponikowski, P, Hua, TA, Greenberg, BH, Filippatos, G, Felker, GM, Cotter, G & Metra, M 2017, 'Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial', American Heart Journal, vol. 187, pp. 62-69. https://doi.org/10.1016/j.ahj.2017.02.024
Pang, Peter ; Teerlink, John R. ; Boer-Martins, Leandro ; Gimpelewicz, Claudio ; Davison, Beth A. ; Wang, Yi ; Voors, Adriaan A. ; Severin, Thomas ; Ponikowski, Piotr ; Hua, Tsushung A. ; Greenberg, Barry H. ; Filippatos, Gerasimos ; Felker, G. Michael ; Cotter, Gad ; Metra, Marco. / Day vs night : Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. In: American Heart Journal. 2017 ; Vol. 187. pp. 62-69.
@article{7fdaa93993df43c5a37b2afa16a9e071,
title = "Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial",
abstract = "Background Signs and symptoms of heart failure can occur at any time. Differences between acute heart failure (AHF) patients who present at nighttime vs daytime and their outcomes have not been well studied. Our objective was to determine if there are differences in baseline characteristics and clinical outcomes between AHF patients presenting during daytime vs nighttime hours within an international, clinical trial. Methods This is a post hoc analysis of the RELAX AHF trial, which randomized 1,161 AHF patients to serelaxin vs placebo, both in addition to usual AHF therapy. Prespecified end points of the primary trial were used: dyspnea, 60-day heart failure/renal failure rehospitalization or cardiovascular (CV) death, and 180-day CV death. Both unadjusted and adjusted analyses for outcomes stratified by daytime vs nighttime presentation were performed. Results Of the 1,161 RELAX-AHF patients, 775 (66.8{\%}) patients presented during daytime and 386 (33.2{\%}) at nighttime. Baseline characteristics were largely similar, although daytime patients were more likely to be male, have greater baseline body weight, have higher New York Heart Association class, have history of atrial fibrillation, and have more peripheral edema compared with nighttime patients. No differences in dyspnea relief or 60-day outcomes were observed. However, daytime presentation was associated with greater risk for 180-day CV death after adjustment (hazard ratio 2.28, 95{\%} CI 1.34-3.86; c statistic = 0.82, 95{\%} CI 0.78-0.86). Conclusion In this secondary analysis of the RELAX-AHF trial, baseline characteristics suggest that daytime-presenting patients may have more gradual worsening of chronic HF. Patients with AHF who presented at night had less risk for 180-day CV death, but similar risk for 60-day CV death or rehospitalization and symptom improvement for patients who presented during the daytime.",
author = "Peter Pang and Teerlink, {John R.} and Leandro Boer-Martins and Claudio Gimpelewicz and Davison, {Beth A.} and Yi Wang and Voors, {Adriaan A.} and Thomas Severin and Piotr Ponikowski and Hua, {Tsushung A.} and Greenberg, {Barry H.} and Gerasimos Filippatos and Felker, {G. Michael} and Gad Cotter and Marco Metra",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.ahj.2017.02.024",
language = "English (US)",
volume = "187",
pages = "62--69",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Day vs night

T2 - Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial

AU - Pang, Peter

AU - Teerlink, John R.

AU - Boer-Martins, Leandro

AU - Gimpelewicz, Claudio

AU - Davison, Beth A.

AU - Wang, Yi

AU - Voors, Adriaan A.

AU - Severin, Thomas

AU - Ponikowski, Piotr

AU - Hua, Tsushung A.

AU - Greenberg, Barry H.

AU - Filippatos, Gerasimos

AU - Felker, G. Michael

AU - Cotter, Gad

AU - Metra, Marco

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background Signs and symptoms of heart failure can occur at any time. Differences between acute heart failure (AHF) patients who present at nighttime vs daytime and their outcomes have not been well studied. Our objective was to determine if there are differences in baseline characteristics and clinical outcomes between AHF patients presenting during daytime vs nighttime hours within an international, clinical trial. Methods This is a post hoc analysis of the RELAX AHF trial, which randomized 1,161 AHF patients to serelaxin vs placebo, both in addition to usual AHF therapy. Prespecified end points of the primary trial were used: dyspnea, 60-day heart failure/renal failure rehospitalization or cardiovascular (CV) death, and 180-day CV death. Both unadjusted and adjusted analyses for outcomes stratified by daytime vs nighttime presentation were performed. Results Of the 1,161 RELAX-AHF patients, 775 (66.8%) patients presented during daytime and 386 (33.2%) at nighttime. Baseline characteristics were largely similar, although daytime patients were more likely to be male, have greater baseline body weight, have higher New York Heart Association class, have history of atrial fibrillation, and have more peripheral edema compared with nighttime patients. No differences in dyspnea relief or 60-day outcomes were observed. However, daytime presentation was associated with greater risk for 180-day CV death after adjustment (hazard ratio 2.28, 95% CI 1.34-3.86; c statistic = 0.82, 95% CI 0.78-0.86). Conclusion In this secondary analysis of the RELAX-AHF trial, baseline characteristics suggest that daytime-presenting patients may have more gradual worsening of chronic HF. Patients with AHF who presented at night had less risk for 180-day CV death, but similar risk for 60-day CV death or rehospitalization and symptom improvement for patients who presented during the daytime.

AB - Background Signs and symptoms of heart failure can occur at any time. Differences between acute heart failure (AHF) patients who present at nighttime vs daytime and their outcomes have not been well studied. Our objective was to determine if there are differences in baseline characteristics and clinical outcomes between AHF patients presenting during daytime vs nighttime hours within an international, clinical trial. Methods This is a post hoc analysis of the RELAX AHF trial, which randomized 1,161 AHF patients to serelaxin vs placebo, both in addition to usual AHF therapy. Prespecified end points of the primary trial were used: dyspnea, 60-day heart failure/renal failure rehospitalization or cardiovascular (CV) death, and 180-day CV death. Both unadjusted and adjusted analyses for outcomes stratified by daytime vs nighttime presentation were performed. Results Of the 1,161 RELAX-AHF patients, 775 (66.8%) patients presented during daytime and 386 (33.2%) at nighttime. Baseline characteristics were largely similar, although daytime patients were more likely to be male, have greater baseline body weight, have higher New York Heart Association class, have history of atrial fibrillation, and have more peripheral edema compared with nighttime patients. No differences in dyspnea relief or 60-day outcomes were observed. However, daytime presentation was associated with greater risk for 180-day CV death after adjustment (hazard ratio 2.28, 95% CI 1.34-3.86; c statistic = 0.82, 95% CI 0.78-0.86). Conclusion In this secondary analysis of the RELAX-AHF trial, baseline characteristics suggest that daytime-presenting patients may have more gradual worsening of chronic HF. Patients with AHF who presented at night had less risk for 180-day CV death, but similar risk for 60-day CV death or rehospitalization and symptom improvement for patients who presented during the daytime.

UR - http://www.scopus.com/inward/record.url?scp=85014842554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014842554&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2017.02.024

DO - 10.1016/j.ahj.2017.02.024

M3 - Article

VL - 187

SP - 62

EP - 69

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -